Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study

References

• Moy B, Lee RJ, Smith M. Natural Products in Cancer Chemotherapy: Hormones and Related Agents. In: Brunton LL, editor. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12 ed. New York: McGraw-Hill; 2011.
   Google Scholar
• Davies C, Godwin J, Gray R, Clarke M, Cutter D. Early Breast Cancer Trialists' Collaborative G. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771–84.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206–23.
   PubMed Web of Science ®Google Scholar
• Kichina J, Goc A, Al-Husein B, Somanath P, Kandel E. PAK1 as a therapeutic target. Expert Opin Therapeutic Target 2010;14:703–25.
   PubMed Web of Science ®Google Scholar
• Wang RA, Vadlamudi RK, Bagheri-Yarmand R, Beuvink I, Hynes NE, Kumar R. Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol 2003;161:583–92.
   PubMed Web of Science ®Google Scholar
• Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 2006;25:2931–6.
   PubMed Web of Science ®Google Scholar
• Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, et al. P21-Activated Kinase 1 Regulation of Estrogen Receptor-alpha Activation Involves Serine 305 Activation Linked with Serine 118 Phosphorylation. Cancer Res 2006;66:1694–701.
   PubMed Web of Science ®Google Scholar
• Balasenthil S, Barnes C, Rayala S, Kumar R. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 2004;567:243–7.
   PubMed Web of Science ®Google Scholar
• Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007;26:6997–7005.
   PubMed Web of Science ®Google Scholar
• Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006;98:671–80.
   PubMedGoogle Scholar
• Holm C, Kok M, Michalides R, Fles R, Koornstra R, Wesseling J, et al. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol 2009;217:372–9.
   PubMed Web of Science ®Google Scholar
• Bostner J, Skoog L, Fornander T, Nordenskjöld B, Stål O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clinical Cancer Res. 2010;16:1624–33.
   PubMed Web of Science ®Google Scholar
• Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer L, et al. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011;125:1–12.
   PubMed Web of Science ®Google Scholar
• Jordan V. Pak up your breast tumor–and grow!. J Nat Cancer Inst 2006;98:657–9.
   PubMedGoogle Scholar
• Lash T, Cronin-Fenton D, Ahern T, Rosenberg C, Lunetta K, Silliman R, et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011;103:489–500.
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Christiansen P, Mouridsen H. Danish Breast Cancer Cooperative Group–DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008;47:497–505. (Stockholm, Sweden).
   PubMed Web of Science ®Google Scholar
• Møller S, Jensen M, Ejlertsen B, Bjerre K, Larsen M, Hansen H, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008;47:506–24.
   PubMed Web of Science ®Google Scholar
• Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
   PubMedGoogle Scholar
• Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011;11:83
   PubMed Web of Science ®Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39:30–3.
   PubMed Web of Science ®Google Scholar
• Andersen K, Mouridsen H. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol 1988;27:627–47.
   PubMed Web of Science ®Google Scholar
• Trikalinos T, Salanti G, Khoury M, Ioannidis J. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol2006;163:300–9.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Greenland S, Lash TL. Case-Control Studies. In: Rothman KJ, Greenland S, Lash TL, editors. Modern Epidemiology. 3rd ed. Philadelphia: Wolters Kluwer; 2008. p. 111–27.
   Google Scholar
• Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Method Med Res 2007;16:219–42.
   PubMed Web of Science ®Google Scholar
• The MIANALYZE Procedure. SAS/STAT User's Guide: The SAS Institute; 2014.
   Google Scholar
• Jensena A, Ewertz M, Cold S, Storm H, Overgaard J. Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark. Eur J Cancer 2003;39:1783–93.
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Hellberg Y, Lauridsen KL, Ahern TP, Garne JP, Rosenberg C, et al. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. Acta Oncol 2012;51:254–61.
   PubMed Web of Science ®Google Scholar
• Aaltonen K, Ahlin C, Amini R, Salonen L, Fjallskog M, Heikkila P, et al. Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. Br J Cancer 2006;94:1697–702.
   PubMed Web of Science ®Google Scholar
• Camp R, Charette L, Rimm D. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943–9.
   PubMed Web of Science ®Google Scholar
• Desai M, Kubo J, Esserman D, Terry MB. The handling of missing data in molecular epidemiology studies. Cancer Epidemiol Biomarkers Prev 2011;20:1571–9.
   PubMed Web of Science ®Google Scholar
• Ryden L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005;41:256–64.
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Johansson H, Stockholm Breast Cancer Study G. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 2007;46:133–45.
   PubMed Web of Science ®Google Scholar
• Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2009;113:275–83.
   PubMed Web of Science ®Google Scholar